Thirty-four patients (87.2%) were male and the median age was 65 years. ECOG performance status was 0–1 in 20 (51.3%) patients and 2 in 19 (48.7%) patients. The median number of chemotherapy cycles was six (range: 1–6 cycles). Thirty-five patients were assessable for response evaluation. The overall response rate was 69.2%(1 CR, 26 PR) under the intent-to-treat analysis. After a median follow-up of 22.7 months, the median time to progression was 6.4 months (95%confidence interval [CI]: 5.7–7.1 months) and median overall survival was 11.0 months (95%CI: 9.9–12.0 months). The estimated 1-year survival rate was 42.5%. In terms of toxicities, Grade 3/4 neutropenia and thrombocytopenia occurred in eight (25.6%) and five (15.4%) patients, respectively. Grade 3/4 non-hematologic toxicities included diarrhea (10.3%), anorexia (7.7%), infection (10.3%), and neutropenic fever (12.8%). There was one treatment-related death due to superimposed infection on the broncho-pleural fistula.
The combination chemotherapy of irinotecan and carboplatin was effective and tolerable in previously untreated ED-SCLC patients.div>div>
direct.com/science?_ob=MImg&_imagekey=B6T9C-4M0S2X1-3-1&_cdi=5111&_user=10&_orig=article&_coverDate=12%2F31%2F2006&_sk=999459996&view=c&wchp=dGLzVlz-zSkzV&md5=56e6ae6ed48be753e72f5a19c827e237&ie=/sdarticle.pdf">direct.com/scidirimg/icon_pdf.gif" alt=""> Purchase PDF (146 K)div>div>
ding:3px 5px 0px 5px"> | di=B6T9C-4SBHS87-D&_orig=article&_acct=C000050221&_version=1&_userid=10&md5=89e8009a78a89e126b12c9a45499efe5">View More Related Articles |
Irinotecan and carboplatin in relapsed small cell lung cancer